Postgraduation Program, Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil.
Thyroid. 2012 May;22(5):482-6. doi: 10.1089/thy.2011.0214. Epub 2011 Dec 16.
In patients with differentiated thyroid carcinoma considered to be free of the disease after initial therapy, the appropriate timing or necessity of subsequent stimulated thyroglobulin (Tg) testing is uncertain. The objective of this study was to determine the value of a repeat stimulated Tg in patients considered to be free of disease 6-12 months after thyroid ablation, and also who continued to have serum Tg <1 ng/mL while on thyrotropin suppressive doses of thyroxine (T4) (Tg/T4), negative anti-Tg antibodies (TgAb), and a normal clinical examination 5 years after their initial therapy.
The study participants were 203 patients who had total thyroidectomy followed by ablation with (131)I, who were considered to be free of disease 6-12 months after ablation (stimulated Tg <2 ng/mL in the absence of TgAb and negative diagnostic whole-body scanning), who had no recurrence, and who continued to have serum Tg/T4 of <1 ng/mL, negative TgAb and a normal clinical examination 5 years after initial therapy. These patients were evaluated with repeat stimulated Tg testing after 4 weeks of T4 withdrawal.
Repeat stimulated Tg values after 5 years were <2 ng/mL in 192 (94.6%) patients of whom 188 were <1 ng/mL. Subsequent follow-up after a mean of 102 months did not detect new cases of tumor recurrence in this subgroup. Eleven patients (5.4%) had stimulated Tg levels of >2 ng/mL. Neck ultrasonography (US) revealed metastases in three and other imaging methods detected metastases in five patients with negative US. In the other three patients, no metastases were detected initially or during follow-up. Gender, age, and tumor stage were not predictors of recurrence or elevated Tg upon repeat testing after 5 years.
The present results favor repeating stimulated Tg 5 years after ablation in patients who were initially considered to be free of disease and who continued to have Tg/T4 values of <1 ng/mL and negative TgAb tests. A negative predictive value of 100% was obtained for patients who continued to have low stimulated Tg values.
在初始治疗后被认为无疾病的分化型甲状腺癌患者中,随后进行刺激甲状腺球蛋白(Tg)检测的适当时间或必要性尚不确定。本研究的目的是确定在甲状腺消融后 6-12 个月被认为无疾病且在甲状腺抑制剂量的左甲状腺素(T4)(Tg/T4)、阴性抗甲状腺球蛋白抗体(TgAb)和初始治疗后 5 年的正常临床检查下仍持续存在血清 Tg<1ng/mL 的患者中,重复刺激 Tg 的价值。
本研究纳入了 203 例接受甲状腺全切除术加放射性碘消融治疗的患者,这些患者在消融后 6-12 个月被认为无疾病(刺激 Tg<2ng/mL 且无 TgAb 且阴性诊断性全身扫描)、无复发且在初始治疗后 5 年仍持续存在血清 Tg/T4<1ng/mL、阴性 TgAb 和正常临床检查。这些患者在 T4 停药 4 周后进行重复刺激 Tg 检测。
在这 203 例患者中,有 192 例(94.6%)患者在 5 年后的重复刺激 Tg 值<2ng/mL,其中 188 例<1ng/mL。在这一亚组中,随后平均 102 个月的随访未发现新的肿瘤复发病例。11 例(5.4%)患者的刺激 Tg 水平>2ng/mL。颈部超声(US)显示 3 例患者有转移,其他影像学方法在 5 例 US 阴性的患者中检测到转移。在另外 3 例患者中,最初或随访期间均未发现转移。性别、年龄和肿瘤分期不是 5 年后重复检测时复发或 Tg 升高的预测因素。
本研究结果支持在初始被认为无疾病且持续 Tg/T4 值<1ng/mL 和阴性 TgAb 检测的患者中,在消融后 5 年重复刺激 Tg。对于持续低刺激 Tg 值的患者,获得了 100%的阴性预测值。